Le Lézard
Classified in: Health
Subjects: NPT, EXE, REL, AVO

FRC Applauds DOJ Guidance Protecting Religious Freedom, Exempting from Oppressive HHS Mandate


WASHINGTON, Oct. 6, 2017 /PRNewswire-USNewswire/ -- Family Research Council applauded two major actions today by the Trump administration that safeguard religious freedom.   The Department of Justice (DOJ) is directing federal agencies to respect religious freedom while the Department of Health and Human Services (HHS) is exempting religious entities from the oppressive Obama contraceptive mandate.

Family Research Council logo (PRNewsFoto/Family Research Council)

Family Research Council President Tony Perkins released the following statement:

"After eight years of the federal government's relentless assault on the First Amendment, the Trump administration has taken concrete steps today that will once again erect a bulwark of protection around American's First Freedom ? religious freedom.  

"President Trump is demonstrating his commitment to undoing the anti-faith policies of the previous administration and restoring true religious freedom.    Last May, the president ordered the federal government to vigorously promote and protect religious liberty ?and now the DOJ and HHS are moving to make that order a reality.  

"Under the Obama administration, agencies lost the understanding that religious freedoms extend to the public square, not just one's place of worship.   As a result, our own government began threatening hardworking, patriotic Americans with crushing fines for simply seeking to live their lives according to their faith.    

"President Trump and the Department of Justice are putting federal government agencies on notice: you will not only respect the freedom of every American to believe but live according to those beliefs.  This is a freedom that has been a fundamental part of our society since the beginning of our nation.

 "To aid the Trump administration's efforts in vigorously promoting and protecting religious liberty, Family Research Council today is launching a web hotline for those who believe that they have suffered discrimination at the hands of federal agencies based on their religious beliefs or practices. The 'Free to Believe' hotline will help ensure that no federal employee, contractor or citizen will be forced to choose between their faith and equal treatment by the federal government.

"As President Trump continues to follow through on his promises on these core issues, he will continue to have the support of social conservatives on his policy initiatives," concluded Perkins.

Click here for more information on the religious hotline:

http://freetobelieve.com/federal 

SOURCE Family Research Council


These press releases may also interest you

at 01:00
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. ? ?  Q1 2024? Q1 2023? % change? ?m? ?m? ActualCER1Growth...

23 avr 2024
GenScript, a global leader in life sciences and biotechnology, successfully hosted an Open Day event at its Singapore facility on the 16th of April, welcoming more than 50 representatives from Singapore. This event provided an exclusive look into...

23 avr 2024
Cybervation, an award-winning global technology and healthcare solutions company, proudly announces that its CEO, Purba Majumder, has been distinguished as one of the 2024 100 Women to KNOW Across America. This award from KNOW Women recognizes...

23 avr 2024
The report titled "Glycated Albumin Assay Market by Product (Animal Glycated Albumin Assay, Human Glycated Albumin Assay), Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User - Global Forecast 2024-2030" is now available on...

23 avr 2024
The report titled "Health & Wellness Food Market by Type (Fresh & Natural, Functional Foods & Beverages, Heat & Eat), Nature (Genetically Modified Organism Food, Non-Genetically Modified Organism Food), Fat Content, Category, Free From Category,...

23 avr 2024
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and...



News published on and distributed by: